Medicortex Finland Announces Patent Approval for Underlying Technology of Drug Development Plan
Medicortex Finland Oy announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent for a product candidate of New Chemical Entity (NCE) for prevention of long term effects of concussion and Traumatic Brain Injury (TBI). The compounds are targeting several biochemical processes of brain deterioration, thus being capable of halting the expansion of destructive secondary injuries typically following the original injury. Such a drug will have a large demand since there is no proper medical treatment available for TBI currently.
First filed and recently issued in Finland, the patent with the name of “Multivalent compounds for use in the treatment and prevention of brain damage” verifies Medicortex’s unique approach to preventing long term effects of head injury and opens up the possibilities for international collaborations. Equivalent applications are still pending in the European Patent Office (EPO) and Israel.
Dr. Adrian Harel, CEO of Medicortex Finland stated "We are pleased to announce the approval of this patent as it provides a basis for developing our first product for TBI treatment as part of our international expansion plan. Importantly, this patent reinforces the uniqueness of our drug development technology" concluded Dr. Harel.
The patent approval within such a high need pharma industry is of great importance and a big break-through for Medicortex Finland.
About Medicortex Finland Oy
Medicortex Finland Oy (http://www.medicortex.fi) is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is to develop biomarker based diagnostics to evaluate the presence and severity of TBI. Once the company completes this diagnostic kit development its next goal will be to develop an innovative drug to halt the progression of brain injury.
This press release contains statements that are "forward-looking statements" that are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
Keywords: head injury, trauma, brain injury, TBI, concussion, diagnostics, NCE, drug development, patent
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy21.5.2019 08:00:00 EEST | Tiedote
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005695/en/ Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to improve outcomes by enabling heart failure (HF) patients, with or without chronic kidney disease (CKD), to be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) therapy in accordance with HF treatment guidelines1,2. Presently, RAASi treatment is frequently discontinued due to the risk of hyperkalaemia (elevated blood potassium levels). The DIAMOND study is designed to further support the use of Veltassa® to effectively control high blood potassium levels, thereby enabling optimal RAASi therapy in HF patients. It is a global, multicentre, double-blind, placebo-controlled trial aiming to study approximately 2,400 patients in over 400 sites. Eligible patients wil
Concierge Auctions and Engel & Völkers to Sell $29.9 Million New Jersey Estate Without Reserve20.5.2019 20:32:00 EEST | Tiedote
A 32,507-square-foot Saddle River residence will sell at auction next month via leading global firm Concierge Auctions. Known as “Stone Palace on the Hill,” the home features a glass elevator, tennis court, racquetball court, wine cellar, and two swimming pools. 144 East Saddle River Road was previously listed for $29.9 million and will sell Without Reserve in cooperation with Alina Pogorelova and Lisa Troyano-Ascolese of Engel & Völkers. Bidding, which will be held via Concierge Auctions’ online marketplace, will open on June 21st and close on June 27. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005686/en/ 144 East Saddle River Road | New York Metro, NJ (Photo: Business Wire) “The quality of work and detail that went into building this home is perhaps the most impressive element of the property,” said Troyano-Ascolese. “With astounding details from custom gold-plated and forged-iron railings to a complete hand-cut
CNIM to Optimize Renewable Heat Production for Nantes District Heating20.5.2019 20:20:00 EEST | Tiedote
CNIM, a French international industrial equipment manufacturer and integrator, has entered into an agreement concerning the energy efficiency optimisation at the waste-to-energy plant serving the cities of Nantes and Saint Nazaire, in the North West of France. Under the terms of this agreement, CNIM will install an absorption heat pump to boost the supply of hot water to Nantes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005678/en/ Heat-Pump_13MW_Brive (c) CNIM The delivery is scheduled for October 2019. The new system has been designed to inject 3.1 MW of heat energy into Nantes' district heating system. 2018: Two contracts to upgrade heat networks in France and Switzerland Prior to this agreement, CNIM won two other major contracts to upgrade the energy efficiency of waste-to-energy plants in France and Switzerland, and to supply district heating networks with renewable energy. Supplying 30 MW to Basel's district
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD120.5.2019 19:46:00 EEST | Tiedote
Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD). Results show that nintedanib slows the loss of pulmonary function in patients with SSc-ILD compared to placebo. Patients taking nintedanib showed a 44% reduction in the rate of decline of their lung function, measured in FVC assessed over 52 weeks1. These new data were today published in the New England Journal of Medicine (NEJM) and presented to the medical community at the American Thoracic Society (ATS) International Conference, in Dallas, USA. SENSCIS® is the largest randomised controlled trial to be conducted in patients with SSc-ILD, a disease for which there are currently no approved treatments.1,3,4 Results also showed that nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibro
MyHeritage laajenee terveyteen lanseeramalla uuden DNA-testin, joka tarjoaa kuluttajille yksilöllistä tietoa terveydestä20.5.2019 18:55:00 EEST | Tiedote
MyHeritage, maailman johtava perhehistoria- ja DNA-testauspalvelu, ilmoitti tänään DNA-tuotevalikoimansa merkittävästä laajenemisesta MyHeritage Terveys+Perimä DNA-testin lanseeraamisen myötä. Testi tarjoaa uuden ulottuvuuden geneettiseen tietoon kattavien terveysraporttien avulla, mikä voi vaikuttaa terveys- ja elämäntapavalintoihin tulevaisuudessa. Se on nykyisen MyHeritage Vain-Perimä DNA-testin supersetti ja sisältää sen peruspilarit: etnisen alkuperän prosentuaalisen jakauman ja yhteisen, jaetun DNAn avulla löytyneet sukulaiset. MyHeritage on nyt ainoa maailmanlaajuinen DNA-yritys, joka tarjoaa kuluttajille kattavan terveys- ja perimä-tuotteen yli 40 kielellä. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20190520005590/fi/ MyHeritage laajenee terveyteen lanseeramalla uuden DNA-testin, joka tarjoaa kuluttajille yksilöllistä tietoa terveydestä (Graphic: Business Wire) Terveys+Perimä-tuotteen lanseeraus erottaa MyHerita
Airship Bolsters its Senior Leadership Team for Accelerated Global Growth20.5.2019 16:00:00 EEST | Tiedote
Customer engagement company Airship today announced four senior leadership appointments including Dale Flores as vice president of sales Americas, Neil Gariepy as vice president of infrastructure and security, David King Harris as vice president of sales EMEA, and Jeff Winsor as vice president of technology services. Dale Flores will lead the rapid expansion of Airship’s Americas sales organization, growing solution adoption to generate greater business value for customers throughout the region. Flores brings two decades of global SaaS sales and customer success management experience to Airship, including over 14 years leading sales teams at Silverpop and IBM. Most recently, Flores was head of customer success at digital customer experience company Clicktale. Neil Gariepy will lead Airship’s customer engineering, infrastructure and security teams, with responsibility for expanding Airship’s infrastructure globally while further optimizing its cost, performance and security. Gariepy bri
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme